Todd C. Brady, President and CEO at Aldeyra Therapeutics, Inc. (ALDX), bought 250,000 shares at $1.67 ($418K) on 2026-06-03, disclosed to the SEC on 2026-06-05.
Aldeyra Therapeutics CEO Todd Brady purchased 250,000 shares at $1.67 on June 3, 2026, marking the largest purchase of his career. This significant insider buying comes as the stock trades near its 52-week low and amidst anticipation for FDA feedback on its dry eye drug candidate.
The stock is currently trading at $1.78, down 62.92% over the last 90 days and 71.17% below its 52-week high of $6.175.
Catalysts include FDA feedback on the dry eye drug candidate reproxalap expected by June 5, 2026, and the CEO's largest-ever purchase of 250,000 shares signaling confidence in the current valuation.
The stock faces significant risk from a 12.98% short interest percentage and the 'make-or-break' nature of the FDA's upcoming decision on the drug's efficacy.
Clearly above the average filing.
| Filing → |
| ALDX | BUY | 2019-12-18 | $102K | — | Filing → |
| ALDX | BUY | 2019-10-02 | $49K | — | Filing → |
| ALDX | BUY | 2019-09-25 | $101K | — | Filing → |